| HOME >> MEDICINE >> TECHNOLOGY |
(1,958)
(2,282)
(14%)General and administrative expenses
(12,896)
(10,701)
21%Total operating expenses(14,854)
(12,983)
14%Operating income 19,840
17,435
14%Other income (expenses), net:Other income (expenses), net
1,627
183
*Interest income (expenses), net
831
98
*Total other income (expenses), net2,458
281
*Income before income taxes22,298
17,716
26%Income tax expense
(4,074)
(2,199)
85%Net income18,224
15,517
17%Basic net earnings per ADS0.26
0.22
15%Diluted net earnings per ADS0.24
0.21
16%Weighted average ADS outstanding—basic 70,419,377
69,075,025Weighted average ADS outstanding—diluted74,944,373
74,230,526* Not meaningful or greater than 100%WUXI PHARMATECH (CAYMAN) INC.RECONCILIATION OF GAAP TO Non-GAAP(in thousands of U.S. dollars, except ADS data and par value data) Three Months Ended March 31,20112010% ChangeGAAP gross profit34,694
30,418
14%GAAP gross margin37%
38%Adjustments:Share-based compensation
975
889
10%Amortization of acquired intangible assets
355
764
(54%)Non-GAAP gross profit36,024
32,071
12%Non-GAAP gross margin39%
40%GAAP operating income19,840
17,435
14%GAAP operating margin21%
22%Adjustments:Share-based compensation
2,937
2,322
26%Amortization of acquired intangible assets
355
764
(54%)Non-GAAP operating income23,132
20,521
13%Non-GAAP operating margin25%
25%GAAP net income18,224
15,517
17%GAAP net margin19%
19%Adjustments:Share-based compensation
2,937
2,322
26%Amortization of acquired intangible as
'/>"/>
| SOURCE WuXi PharmaTech (Cayman) Inc Copyright©2010 PR Newswire. All rights reserved |